EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DLY | 13.12 | 0.02 | +0.15% |
| DoubleLine Yield Opportunities Fund | |||
| FLOT | 50.99 | 0.04 | +0.08% |
| iShares Floating Rate Bond ETF (FLOT) | |||
| SBND | 18.34 | N/A | N/A |
| Columbia Short Duration Bond ETF (SBND) | |||
| OCTT | 48.50 | -0.36 | -0.73% |
| AllianzIM U.S. Equity Buffer10 Oct ETF (OCTT) | |||
| CSCL | 48.87 | -2.38 | -4.64% |
| Direxion Daily CSCO Bull 2X ETF (CSCL) | |||
A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with ATHE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then ATHE could also see price increases.
| Ticker / NAME | Correlation To EYPT | 1D Price Change % | ||
|---|---|---|---|---|
| EYPT | 100% | -4.78% | ||
| ATHE - EYPT | 54% Loosely correlated | -3.68% | ||
| KROS - EYPT | 40% Loosely correlated | -3.96% | ||
| AMLX - EYPT | 38% Loosely correlated | -4.74% | ||
| KYTX - EYPT | 37% Loosely correlated | -5.03% | ||
| VTGN - EYPT | 37% Loosely correlated | -6.10% | ||
More | ||||
a developer of ophthalmic pharmaceuticals
Industry Biotechnology
The Aroon Indicator for EYPT entered a downward trend on October 16, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 326 similar instances where the Aroon Indicator formed such a pattern. In 296 of the 326 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EYPT as a result. In 63 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EYPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EYPT's RSI Oscillator exited the oversold zone, 36 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +9.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where EYPT advanced for three days, in 247 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
EYPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.715) is normal, around the industry mean (26.782). P/E Ratio (18.740) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.380) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (101.010) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. EYPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EYPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.